WHO recommends against Remdesivir when FDA authorizes its co
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
On November 19, the World Health Organization panel recommended against the use of the antiviral remdesivir in hospitalized Covid-19 patients, saying there is no evidence that the drug reduces mortality.

However, on the same day, FDA separately issued an emergency use authorization (EUA) of the drug baricitinib in combination with remdesivir for hospitalized Covid-19 patients who need supplemental oxygen.

WHO’s Guideline Development Group said that it now has a “weak or conditional recommendation against” using remdesivir in hospitalized patients because of clinical trial data that showed the drug did not increase survival.

Gilead staunchly defended what it says are the benefits of remdesivir, citing the NIH-sponsored trial and other studies that found remdesivir helped Covid-19 patients recover and get out of the hospital faster than placebo. “We are disappointed the WHO guidelines appear to ignore this evidence.” the company said.

Study results from the WHO’s Solidarity trial last month showed that remdesivir and other drugs studied “appeared to have little or no effect on hospitalized Covid-19, as indicated by overall mortality, initiation of ventilation, and duration of hospital stay.”

A week after the Solidarity data came out, the FDA approved remdesivir for hospitalized patients. In its approval statement, the FDA did not mention the Solidarity trial, instead citing the NIH-run study as well as other trials that indicated some benefit from remdesivir for improved patient symptoms.

Many infectious disease physicians have taken the view that even if remdesivir is not a total saviour of a medication, it may help some patients, particularly if it can be delivered relatively early in the course of someone’s illness. Plus, some physicians say, they don’t have other therapeutic options that go after the virus itself, so it’s worth continuing to use.


a●●●●i s●●●●●●●n and 26 others like this27 shares
Dr. L●●l S●●●●●a
Dr. L●●l S●●●●●a General Medicine
Remidahavar is not total saviour of the treatment but it is found to be qiete supportive to combine it with treatment.
Nov 20, 2020Like1
Dr. M●●●●●v D●●●i
Dr. M●●●●●v D●●●i Internal Medicine
We have only two specific antiviral drugs, Favipiravir and Remdesivir, if we don' t use any one, we may be accused for deficiency of services (we may not loose in consumer court, as both are still experimental approvals), but patients and relatives would demand, also peer pressure. Secondly they are quite safe barring few precautions to be observed during their administration. Thirdly they are not as expensive as in USA (Remdesivir cost of one course is between 2to 3 thousands dollars depending upon insurance cover). I would consider Remdesivir, if 5 days of Favipiravir did not work (patient has persistent fever, high inflammatory markers or SpO2 around 93 to 94\% without oxygen supplement. WHO has suggested not to give in hospitalized patients, meaning there by in moderate to severe cases, it has no mortality benefits. We need Indian guidelines and also have to await for IDSA guidelines.... Read more
Nov 21, 2020Like28
Dr. M●●●●●v D●●●i
Dr. M●●●●●v D●●●i Internal Medicine
We should also await for IDSA guidelines which would give some authentic management guidance.
Nov 21, 2020Like7